Immunic (IMUX) Competitors

Immunic logo
$7.71 +0.38 (+5.23%)
As of 10:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

IMUX vs. OCS, ASMB, CTNM, FENC, and AVIR

Should you buy Immunic stock or one of its competitors? Immunic's main competitors and comparable companies include Oculis (OCS), Assembly Biosciences (ASMB), Contineum Therapeutics (CTNM), Adherex Technologies (FENC), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Immunic compare to Oculis?

Oculis (NASDAQ:OCS) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Immunic had 16 more articles in the media than Oculis. MarketBeat recorded 24 mentions for Immunic and 8 mentions for Oculis. Oculis' average media sentiment score of 0.76 beat Immunic's score of 0.01 indicating that Oculis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunic
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oculis presently has a consensus price target of $38.57, indicating a potential upside of 413.60%. Immunic has a consensus price target of $35.43, indicating a potential upside of 383.34%. Given Oculis' higher probable upside, equities research analysts plainly believe Oculis is more favorable than Immunic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Immunic
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
2.93

Immunic has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$1.45M300.30-$119.44M-$1.71N/A
ImmunicN/AN/A-$97.17M-$4.07N/A

Oculis has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Immunic has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunic has a net margin of 0.00% compared to Oculis' net margin of -8,613.92%. Oculis' return on equity of -39.24% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-8,613.92% -39.24% -33.45%
Immunic N/A -136.26%-100.75%

Summary

Immunic beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Immunic compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Immunic has a net margin of 0.00% compared to Assembly Biosciences' net margin of -16.57%. Assembly Biosciences' return on equity of -4.40% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
Assembly Biosciences-16.57% -4.40% -3.86%
Immunic N/A -136.26%-100.75%

In the previous week, Immunic had 17 more articles in the media than Assembly Biosciences. MarketBeat recorded 24 mentions for Immunic and 7 mentions for Assembly Biosciences. Immunic's average media sentiment score of 0.01 beat Assembly Biosciences' score of -0.77 indicating that Immunic is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Assembly Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative
Immunic
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Assembly Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Immunic has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Assembly Biosciences currently has a consensus target price of $46.50, indicating a potential upside of 106.67%. Immunic has a consensus target price of $35.43, indicating a potential upside of 383.34%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Assembly Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Immunic
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
2.93

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Assembly Biosciences has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assembly Biosciences$72.30M6.37-$6.12M$0.8127.78
ImmunicN/AN/A-$97.17M-$4.07N/A

Summary

Immunic beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.

How does Immunic compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Contineum Therapeutics' return on equity of -25.48% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -25.48% -24.28%
Immunic N/A -136.26%-100.75%

In the previous week, Immunic had 22 more articles in the media than Contineum Therapeutics. MarketBeat recorded 24 mentions for Immunic and 2 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.96 beat Immunic's score of 0.01 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Contineum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunic
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Contineum Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Immunic has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Contineum Therapeutics currently has a consensus target price of $21.40, indicating a potential upside of 124.08%. Immunic has a consensus target price of $35.43, indicating a potential upside of 383.34%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Contineum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Immunic
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
2.93

51.8% of Immunic shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Contineum Therapeutics has higher revenue and earnings than Immunic. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M7.50-$59.98M-$1.77N/A
ImmunicN/AN/A-$97.17M-$4.07N/A

Summary

Contineum Therapeutics and Immunic tied by winning 7 of the 14 factors compared between the two stocks.

How does Immunic compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Immunic had 13 more articles in the media than Adherex Technologies. MarketBeat recorded 24 mentions for Immunic and 11 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.79 beat Immunic's score of 0.01 indicating that Adherex Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adherex Technologies
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Immunic
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adherex Technologies has a net margin of 2.52% compared to Immunic's net margin of 0.00%. Adherex Technologies' return on equity of 8.96% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies2.52% 8.96% 4.90%
Immunic N/A -136.26%-100.75%

Adherex Technologies has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$44.64M10.71-$9.74M$0.011,358.00
ImmunicN/AN/A-$97.17M-$4.07N/A

Adherex Technologies currently has a consensus target price of $17.25, indicating a potential upside of 27.03%. Immunic has a consensus target price of $35.43, indicating a potential upside of 383.34%. Given Immunic's higher probable upside, analysts clearly believe Immunic is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00
Immunic
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
2.93

Adherex Technologies has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Immunic has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

55.5% of Adherex Technologies shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Adherex Technologies beats Immunic on 11 of the 16 factors compared between the two stocks.

How does Immunic compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Atea Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 102.02%. Immunic has a consensus price target of $35.43, indicating a potential upside of 383.34%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
Immunic
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
3 Strong Buy rating(s)
2.93

Atea Pharmaceuticals has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Immunic has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, Immunic had 20 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 24 mentions for Immunic and 4 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.56 beat Immunic's score of 0.01 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atea Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immunic
4 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atea PharmaceuticalsN/AN/A-$158.35M-$1.95N/A
ImmunicN/AN/A-$97.17M-$4.07N/A

Atea Pharmaceuticals' return on equity of -69.91% beat Immunic's return on equity.

Company Net Margins Return on Equity Return on Assets
Atea PharmaceuticalsN/A -69.91% -61.22%
Immunic N/A -136.26%-100.75%

Summary

Immunic beats Atea Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMUX vs. The Competition

MetricImmunicPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$119.83M$13.51B$7.69B$11.70B
Dividend YieldN/A2.58%2.47%4.46%
P/E Ratio-1.8528.8633.9829.89
Price / SalesN/A7.298.475.70
Price / CashN/A15.6321.0121.89
Price / Book1.175.414.483.75
Net Income-$97.17M$2.88B$3.51B$393.66M
7 Day Performance-5.01%-4.47%-5.55%-5.43%
1 Month Performance10.66%-4.86%-4.18%-6.76%
1 Year Performance1.49%-7.02%-1.56%-7.01%

Immunic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMUX
Immunic
2.7661 of 5 stars
$7.71
+5.2%
$35.43
+359.3%
+0.4%$119.83MN/AN/A95
OCS
Oculis
2.8336 of 5 stars
$7.76
+3.6%
$38.89
+401.1%
-60.8%$422.13M$1.45MN/A60
ASMB
Assembly Biosciences
1.9116 of 5 stars
$21.79
+6.7%
$46.50
+113.4%
-38.1%$404.57M$72.30M19.4873
CTNM
Contineum Therapeutics
1.8167 of 5 stars
$10.30
+8.2%
$21.50
+108.7%
-14.3%$368.31M$50MN/A51
FENC
Adherex Technologies
4.734 of 5 stars
$10.83
+10.4%
$17.00
+57.0%
+55.2%$364.47M$44.64MN/A35

Related Companies and Tools


This page (NASDAQ:IMUX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners